权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecularly regulated release of angiogenic factors from superporous hydrogels

超孔水凝胶中血管生成因子的分子调控释放

基本信息

批准号：
9114155
负责人：
Yong Wang
金额：
$ 42.96万
依托单位：
PENNSYLVANIA STATE UNIVERSITY, THE
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-08-01 至 2020-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9114155
关键词：
Affinity Angiogenic Factor Architecture Attention Binding Biocompatible Materials Biological Assay Blood Vessels Bolus Infusion Cell Survival Cells Chronic Competitive Binding Complex Data Development Diabetic wound Disease Disease model Dose Exhibits Future Generations Growth Health Hydrogels Implant In Vitro Injection of therapeutic agent Investigation Ischemia Kinetics Lead Link Localized Disease Methods Molecular Mus Myocardial Infarction Nucleic Acids Organ Oxygen Physical Stimulation Polymers Procedures Process Property Site Specificity Staging Stroke Structure-Activity Relationship System Technology Testing Time Tissue Engineering Tissues Transport Process Ultrasonography Vascular Endothelial Growth Factors Vascularization Work angiogenesis aptamer base cell growth controlled release design dosage improved in vivo injured novel novel strategies nutrition platelet-derived growth factor BB release factor repaired response systemic toxicity therapeutic angiogenesis

项目摘要

DESCRIPTION: Vascularization is important for the treatment of various ischemic diseases and the survival of tissue-engineered constructs. Thus, the development of angiogenesis strategies has continuously attracted great attention in various fields. However, the realization o successful angiogenesis is challenging, because vascular formation and maturation involve multiple growth factors at different stages. Moreover, while insufficient angiogenic factors do not induce effective angiogenesis, excess angiogenic factors can lead to the formation of defective and leaky blood vessels. Thus, therapeutic angiogenesis requires not only multiple growth factors, but also mechanisms for modulating the time, dosage, and sequential order of growth factor delivery. While bolus injections are the simplest way to control the time, dosage, and sequential order of growth factor delivery, this mode of delivery requires very high levels of growth factors. It can lead to severe systemic toxicity. By contrast, polymeric delivery systems hold great promise for localized delivery of growth factors with reduced systemic toxicity. However, it is challenging to develop a polymeric system to control the release time, dosage and sequential order of multiple growth factors. The objective of this application is to develop a novel molecularly controlled release mechanism and a hydrogel-based polymeric system that can release multiple angiogenic factors with differential and independent timing and dose control, hence regulating angiogenesis in a dynamic manner. The central hypothesis is that multiple growth factors would be sequestered within the same hydrogel by specific binding to hydrogel-linked nucleic acid aptamers, and released specifically by competitive binding of complementary sequence (CS) triggers. To test this hypothesis, we will work on three specific aims: 1) to synthesize aptamer-functionalized superporous hydrogels (AS-gels) for high-capacity sequestration and retention of multiple growth factors; 2) to design and optimize aptamer and CS sequences and to determine molecularly regulated growth factor release from AS-gels in vitro; and 3) to investigate molecularly regulated growth factor release from AS-gels and angiogenesis in mice. We have performed preliminary studies and acquired compelling data showing that AS-gels can sequester growth factors and release them in the presence of CS triggers. More importantly, AS-gels can be triggered to release growth factors to stimulate angiogenesis in vivo. Therefore, the accomplishment of this project will lead to a novel strategy for on-demand delivery of multiple growth factors. It will benefit the treatment of various ischemic diseases such as repair of internal organs where it is too harmful or impossible to repeatedly inject growth factors directly into the tissue.